Quick Facts

• Primary Use: Management of congenital Factor XIII (FXIII) deficiency.
• Prophylaxis: Employed for the routine prevention of bleeding episodes.
• Surgical Use: Used for the management of bleeding around the time of surgery.

Fibrogammin P is a therapeutic option used for individuals with congenital Factor XIII (FXIII) deficiency. This rare condition can lead to recurrent bleeding events and potential disturbances in wound healing.

Its primary use is for the routine prophylactic treatment in both adult and pediatric patients with this deficiency. Prophylaxis may help reduce the frequency of spontaneous bleeding events over time.

The medication also serves a role in the peri-operative management of surgical bleeding, helping to mitigate blood loss and support hemostasis during and after surgical procedures. The goal of administration is to maintain plasma FXIII activity levels within a certain range to support clot stability and help manage bleeding risk.

Who Can and Cannot Use Fibrogammin P

This section outlines the population eligibility rules for Fibrogammin P (Human Factor XIII Concentrate), based strictly on official regulatory labeling. Eligibility is defined by the patient's underlying condition, allergic history, and specific clinical circumstances.

Official Eligibility and Contraindications

Classification	Population Rule
Eligible Population	Use is established and indicated for adult and paediatric patients with congenital Factor XIII (FXIII) deficiency.
Absolute Contraindication	The medicine must not be used by individuals with a documented history of anaphylactic or severe systemic reactions to any component in the formulation or to human plasma-derived products.

Restrictions and Special Considerations

Fibrogammin P is generally permitted across all age groups, but official documents require caution when administered to patients with fresh thromboses (recent blood clots) due to the fibrin-stabilizing effect of the medication.

Regulatory information states that use may be considered during pregnancy, if necessary, and can be used during breastfeeding. There are no specific contraindications documented in primary labeling based solely on hepatic or renal impairment.

Interactions with other medicines and products

Official regulatory documentation for Fibrogammin P (Coagulation Factor XIII, Human) primarily addresses an administration incompatibility rather than classical drug–drug interactions.

---

Administration Compatibility and Procedural Restrictions

The most critical restriction noted in the prescribing information is the physical and chemical incompatibility of the product with other substances. This leads to mandatory procedural constraints:

• Prohibited Mixing: Coagulation Factor XIII, Human must not be mixed with any other medicinal products, solvents, or diluents, with the exception of the specific sterile water provided for reconstitution.
• Separate Infusion Line: Administration requires strict isolation. The medicine must be administered through a separate, dedicated intravenous infusion line to avoid interaction with or precipitation from other solutions.

---

Undocumented Pharmacologic Interactions

Official regulatory labels contain no explicit statements regarding pharmacokinetic interactions, such as those mediated by the cytochrome P450 enzyme system, or specific pharmacodynamic interactions with other therapeutic drug classes. Therefore, no formal dose adjustments or co-administration prohibitions, aside from the physical one, are officially documented in these categories.

The mechanism of Fibrogammin P is a direct replacement therapy supplying a deficient protein necessary for intrinsic blood clot formation. This biologically precise mechanism operates strictly within the coagulation cascade, with activity dependent upon the injury-triggered activation of the coagulation cascade.

The drug supplies the missing Coagulation Factor VIII protein, which functions as an activated cofactor (FVIIIa). FVIIIa is essential for assembling the intrinsic Tenase complex on the surface of activated platelets alongside Factor IXa. This complex formation provides the necessary structural and enzymatic components for assembly that addresses the functional deficit inherent in the intrinsic clotting pathway.

Once formed, the Tenase complex acts as a highly efficient catalytic accelerator, dramatically increasing the rate at which Factor X is converted to Factor Xa. This critical step drives a massive downstream burst of Thrombin generation. Thrombin's subsequent action converts soluble blood proteins into a stable, insoluble Fibrin meshwork, thereby compensating for the deficiency and restoring the capacity for thrombin generation and fibrin formation.

The mechanism's functionality is constrained by the immune system: the effect is neutralized if alloantibodies (inhibitors) bind to the Factor VIII protein, preventing it from performing its cofactor function.

How Fibrogammin P is Used

The use of Fibrogammin P, a plasma-derived Factor XIII (FXIII) concentrate, adheres to a protocol to ensure proper replacement therapy. The medicine is administered exclusively via the intravenous (IV) route and is not formulated for oral or other routes. As a lyophilized powder, the medication requires reconstitution with the provided solvent immediately prior to use; the vial must be swirled gently and never shaken.

---

Official Dosing and Frequency

Administration is structured around the patient’s clinical need, with a weight-based regimen for both routine prevention and acute intervention. Dosing is calculated in International Units per kilogram (IU/kg) of body weight.

Use Pattern	Standard Dose (Approx.)	Frequency	Procedural Note
Routine Prophylaxis	40 IU/kg	Typically once every 28 days	Long-term, cyclic treatment
Acute Management	15 to 20 IU/kg	Every 7 to 14 days (as required)	For acute bleeding or peri-operative use

For routine prophylaxis, the goal is to maintain plasma FXIII trough activity within a defined therapeutic range, which may require periodic adjustments of 5 IU/kg by a healthcare professional. If a scheduled dose is missed, it should be administered as soon as possible, and the patient should then resume the standard 28-day schedule.

---

Administration Requirements

The reconstituted solution must be administered promptly and infused slowly at a rate not to exceed 4 mL per minute. It is a critical procedural constraint that the solution must not be mixed with any other intravenous medicinal products or diluents in the same infusion line. The standard guidelines for pediatric patients generally follow the same weight-based dosing and four-week frequency as adults.

Research Evidence / Overview of Studies for Factor XIII Concentrate (Fibrogammin P)

---

Evidence for Routine Prophylactic Use in Congenital Factor XIII Deficiency

Factor XIII Concentrate was studied for routine, preventative management in individuals diagnosed with congenital Factor XIII deficiency, a condition characterized by fluctuating or episodic manifestations of bleeding. Research, including prospective clinical studies, examined whether Factor XIII levels remained above a measured activity threshold. These studies primarily monitored the minimum Factor XIII activity levels in the blood, as well as the number of bleeding episodes. The findings describe patterns observed in the studies where individuals receiving routine concentrate administrations were observed to have Factor XIII activity above specific levels, and data show patterns related to the number of serious bleeding episodes observed in the studied population compared to non-prophylactic periods. Follow-up durations were limited and sample sizes were modest, reflecting the rarity of this condition.

Evidence for Peri-operative Management of Surgical Bleeding

Factor XIII Concentrate was evaluated in research settings involving surgical procedures in patients with known congenital Factor XIII deficiency. These studies explored how the administration of the concentrate before and/or during surgery related to clotting mechanisms when outcomes describing episodic or acute changes in bleeding risk was observed in a concern. The research describes patterns where Factor XIII concentrate administration was associated with measured Factor XIII activity levels in the observed populations. The focus was on the descriptive patterns of bleeding during surgery in the observed populations. Evidence quality varies across studies, and comparative evidence is lacking against other supportive measures for complex procedures.

Long-term Follow-up and Durability of Descriptive Patterns

Studies used in research exploring how symptoms change over time beyond the first year of treatment monitored patients for several years, focusing on the sustained measurements of Factor XIII activity levels. While research highlights changes measured during the study period related to Factor XIII activity levels, long-term effects are not fully established regarding non-bleeding-related health outcomes. Studies exploring long-term outcomes, including those reflecting daily functioning or activity level, are limited.

Evidence in Special Populations

Factor XIII Concentrate was evaluated in studies that included children, adolescents, and pregnant individuals to understand the descriptive patterns of use and observed activity levels across different ages and high-risk periods. For pediatric populations, data show patterns related to Factor XIII activity levels were monitored for prophylaxis. However, subgroup findings are uncertain when looking at infants due to the small numbers studied. For pregnancy and delivery, case reports and small series describe patterns observed in the use of the concentrate; however, evidence remains limited in these specific populations.

Common questions about Fibrogammin P (FAQ)

Q: Is Fibrogammin P a Factor XIII or Factor VIII concentrate?

According to official regulatory documents and product descriptions, Fibrogammin P is a concentrated product of Human Coagulation Factor XIII (FXIII). It is intended for use as a replacement therapy to address Factor XIII deficiency.

---

Q: What is the specific therapeutic range (trough level) for Factor XIII activity?

Official prescribing information indicates that for routine preventative treatment (prophylaxis), the treatment goal is to maintain a minimum blood level of Factor XIII (FXIII) activity. This Factor XIII trough activity level should be maintained between 5% and 20% of normal activity.

---

Q: What are the signs of an allergic reaction to Fibrogammin P?

As noted in the safety information, signs of a serious allergic or hypersensitivity reaction may include several symptoms. These can involve hives, rash, itching (pruritus), redness (erythema), or systemic reactions such as a feeling of tightness in the chest, wheezing, or low blood pressure (hypotension).

---

Q: How long can the reconstituted solution be stored before use?

The solution must be used immediately after mixing with the provided solvent because it contains no preservatives. Official guidelines state that while the chemical stability is documented for 24 hours, the solution must be administered within 4 hours after reconstitution to meet microbiological safety standards.

How to Store and Dispose of Fibrogammin P?

The unopened vial of Fibrogammin P powder and its solvent must be stored in a refrigerator at a temperature range of +2 C to +8 C. It is mandatory that the product, both before and after reconstitution, must not be frozen. The vial must be kept in its outer carton to protect it from light, and the medicine must be stored out of the sight and reach of children.

---

Stability and Disposal

While chemical stability is documented for 24 hours at 25 C after mixing, the solution should be used immediately from a microbiological perspective. All partially used vials and associated administration materials must be discarded as pharmaceutical waste and must not be disposed of with household rubbish or allowed to enter waterways, in accordance with local regulatory guidelines.